Discover CLSA’s Digital Campaign Opposing SB 1010 and Learn about Recent News and Events
President & CEO
CLSA – California Life Sciences Association
June 20, 2016
Welcoming New Members
Please welcome our newest CLSA members: Aquinox Pharmaceuticals and ExVivo Labs! These great organizations join our 750+ membership portfolio and add significantly to the expertise and resources available in the CLSA network.
BIO 2016 and The California Pavilion
As most of you know, the most influential biotech convention in the world came to San Francisco June 6 – 9. I am pleased to report that there were 15,937 industry leaders in attendance with 40 percent being C-Level attendees. Additionally, 35,700 Partnering Meetings took place, a 23 percent increase over 2015.
With 1,800 exhibitors CLSA remained at the forefront with our California Pavilion. Visitors were able to meet and learn from California’s top industry leaders and attend 13 coveted programming sessions that included a release of two CLSI-led reports, a book signing from BIO keynote speaker, Dr. Bennet Omalu, a visit from University of California President Janet Napolitano and more.
As the voice of California’s life sciences sector representing over 750 members up and down the state, California Life Sciences Association was honored to be a regional host and partner for the 2016 BIO Convention. We look forward to welcoming attendees back to the Golden State next year for the 2017 BIO International Convention in San Diego, as well as the 2017 AdvaMed MedTech Conference in San Jose.
Patients, CLSA Launch Digital Campaign Opposing SB 1010; LA Times Publishes CLSA Response to Editorial
On May 20, CLSA launched a coalition effort to oppose SB 1010, flawed legislation in Sacramento packaged as a manufacturer pricing “transparency” measure that not only does nothing to protect patient access and affordability, but threatens to facilitate medicine hoarding and price-gouging by shady secondary “gray-market” wholesalers and distributors.
The undertaking includes a digital campaign, which can be found at www.protectaccessandinnovation.org, to ensure Sacramento lawmakers understand the consequences of this misleadingly characterized legislation.
I’m also pleased to announce that the LA Times published a Letter to the Editor from CLSA, submitted in response to a misleading editorial they published backing the bill.
The letter, (“Healthcare expenses are a problem, but drug costs aren’t the reason why”) highlights the fact that SB 1010 creates additional red tape and leads to gray-market prescription drug stockpiling. Click here to view the letter at the LA Times. Additional information on SB 1010 and CLSA’s leadership in opposing the measure – including how you can add your voice – can be found in this month’s Bulletin (below).
CLSI Releases 2016 Economic Impact of Bay Area Startups Report at BIO International Convention
On June 7, our partner organization, the California Life Sciences Institute (CLSI), released a report on the economic impact of 137 pre-Series A life sciences startups at a program at the California Pavilion at the 2016 BIO International Convention. The program was followed by a panel and reception with some of the Bay Area’s leading incubators and accelerators, including Bayer CoLaborator, Illumina Accelerator and JLABS. The report took a look at funds raised, patents filed, employee headcount, and percentage of women-led companies, demonstrating a strong impact on the local economy. Click here to view the full report, click here to view the press release or click here to view a BioBuzz video on the report.
In addition, CLSI & the Biocom Institute released the 2016 California Workforce Trends report at BIO with a panel that included Cal Poly President and CLSA Board Member Jeffrey D. Armstrong. Click here to learn more.
CLSA Expands Advocacy Team, Welcomes Senior Director of State Government Relations
I’m pleased to announce that CLSA has appointed a new Senior
Director of State Government Relations, Michael Bolden!
Based in CLSA’s Sacramento office, Bolden will conduct strategic lobbying activities to support and advance the organization’s state advocacy priorities. Bolden comes to CLSA after nearly five years with the California State Council of the Service Employees International Union as a Government Relations Advocate, one and a half years with the California State Senate as an Executive Principal Consultant (Public Employment and Retirement Committee) and nearly four years as the Political and Legislative Advocate for the American Federation of State, County and Municipal Employees, AFL-CIO. Bolden is an exceptional addition to the California Life Sciences Association team. His experience will further strengthen CLSA’s influential advocacy and outreach activities with our legislature and the Administration in Sacramento.
Click here to view the announcement press release, and learn more about other advocacy team changes, including the promotions of Jenny Carey, Reese Isbell and Will Zasadny.
Merck, Organovo and St. Jude Medical Leaders Join CLSA Board of Directors
Ben Thorner, Vice President, BD&L and Head of North American Innovation Hubs, Merck; Keith Murphy, Chairman and Chief Executive Officer, Organovo; and Dave Anderson, Vice President, Merger & Acquisition Integration, St. Jude Medical, will help shape CLSA’s agenda and organizational goals as we focus on our collective mission of helping grow and foster California’s world-leading life sciences sector. These leaders and their respective organizations exemplify the depth and range of CLSA’s membership and what we stand for in advancing hope for patients and consumers in California, across our country and around the world. Click here to learn more.
President & CEO
California Life Sciences Association
PS – Have newsworthy items to submit for consideration for our monthly CLSA Bulletin? Feel free to send those tips to Bianca Leveriza, CLSA’s Associate, Marketing & Events (BLeveriza@CALifeSciences.org).